Andrew Polovin Sells 7,927 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 7,927 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $56.00, for a total value of $443,912.00. Following the completion of the transaction, the executive vice president directly owned 138,140 shares in the company, valued at $7,735,840. The trade was a 5.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Polovin also recently made the following trade(s):

• On Tuesday, August 18th, Andrew Polovin sold 22,148 shares of Tempus AI stock. The shares were sold at an average price of $49.61, for a total value of $1,098,762.28.

Tempus AI Trading Up 9.1%

TEM stock opened at $72.69 on Friday. The business has a fifty day moving average price of $52.93 and a 200 day moving average price of $51.36. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. Tempus AI, Inc. has a fifty-two week low of $40.77 and a fifty-two week high of $104.32. The stock has a market capitalization of $13.12 billion, a price-to-earnings ratio of -50.48 and a beta of 3.58.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business’s revenue was up 21.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. Analysts expect that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TEM. HC Wainwright decreased their price objective on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a report on Monday, August 3rd. Guggenheim boosted their target price on shares of Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. BTIG Research increased their price target on shares of Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a report on Monday, July 20th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tempus AI currently has an average rating of “Hold” and a consensus target price of $65.69.

Institutional Investors Weigh In On Tempus AI

Institutional investors have recently modified their holdings of the business. JPL Wealth Management LLC acquired a new position in Tempus AI in the third quarter valued at approximately $26,000. Los Angeles Capital Management LLC bought a new position in Tempus AI in the fourth quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd acquired a new stake in Tempus AI during the 3rd quarter worth $38,000. EMC Capital Management acquired a new stake in Tempus AI during the 2nd quarter worth $29,000. Finally, Danske Bank A S acquired a new stake in Tempus AI during the 3rd quarter worth $48,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target for Tempus AI to $80 from $70 and maintained a “Buy” rating. The higher target strengthens the bullish case and provides a near-term catalyst for the stock. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is building around Tempus AI’s planned approximately $1.5 billion all-stock acquisition of Personalis. The deal could expand Tempus’ genomic-data, cancer-testing and drug-development capabilities, potentially increasing its strategic value in precision medicine. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Merck and Moderna’s cancer-vaccine trial developments have heightened interest in oncology data and genomic testing. The connection to Tempus is indirect, but the news reinforces the company’s cancer-data and personalized-treatment growth narrative. Tempus AI stock move and Merck-Moderna trial news
• Positive Sentiment: Trading activity in TEM call options was unusually high, with reported volume roughly 57% above normal. This indicates bullish speculation and may be amplifying the stock’s momentum, though options activity can also increase volatility.
• Neutral Sentiment: The stock has moved above its 50-day and 200-day moving averages, raising the possibility of momentum buying or a short squeeze. That technical strength could support further gains, but it also increases the risk of a sharp reversal.
• Negative Sentiment: Tempus AI’s CEO, CFO, EVP and chief accounting officer sold shares, with the largest reported transaction involving CEO Eric Lefkofsky. The sales reduced executives’ holdings and may concern investors, but they were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.